Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.65 USD
Change Today +0.0537 / 9.05%
Volume 1.2M
As of 8:04 PM 06/29/15 All times are local (Market data is delayed by at least 15 minutes).

cel-sci corp (CVM) Snapshot

Open
$0.64
Previous Close
$0.59
Day High
$0.69
Day Low
$0.62
52 Week High
07/1/14 - $1.30
52 Week Low
12/10/14 - $0.54
Market Cap
72.4M
Average Volume 10 Days
673.4K
EPS TTM
$-0.46
Shares Outstanding
111.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CEL-SCI CORP (CVM)

Related News

No related news articles were found.

cel-sci corp (CVM) Related Businessweek News

No Related Businessweek News Found

cel-sci corp (CVM) Details

CEL-SCI Corporation engages in the research and development of drugs and vaccines. The company’s lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. Multikine is also being used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System (LEAPS), a patented T-cell modulation process, stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune, allergies, transplantation rejection, and cancer. The company, through its LEAPS technology, provides peptide treatment for H1N1 hospitalized patients; and CEL-2000, a rheumatoid arthritis vaccine. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.

cel-sci corp (CVM) Top Compensated Officers

Chief Executive Officer, Treasurer and Direct...
Total Annual Compensation: $584.6K
Founder, Chairman and President
Total Annual Compensation: $393.3K
Senior Vice President of Operations and Corpo...
Total Annual Compensation: $247.9K
Senior Vice President of Research - Cellular ...
Total Annual Compensation: $213.2K
Senior Vice President of Regulatory Affairs
Total Annual Compensation: $197.4K
Compensation as of Fiscal Year 2014.

cel-sci corp (CVM) Key Developments

CEL-SCI Corporation Presents at BIO International Convention 2015, Jun-17-2015 04:15 PM

CEL-SCI Corporation Presents at BIO International Convention 2015, Jun-17-2015 04:15 PM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: Geert R. Kersten, Chief Executive Officer, Treasurer and Director.

CEL-SCI Clears to Start Patient Enrollment for its Phase 3 Cancer Immunotherapy Trial in Thailand

CEL-SCI Corporation announced that CEL-SCI is now cleared to start patient enrollment in Thailand in its ongoing Phase 3 trial with its investigational cancer immunotherapy Multikine (Leukocyte Interleukin, Injection) in patients with advanced primary (not yet treated) head and neck cancer. Thailand is the 24th country to authorize CEL-SCI’s Phase 3 trial for patient enrollment. As of May 31, 2015, 463 patients had been enrolled in the global Phase 3 study.

CEL-SCI Corporation Receives Authorization to Conduct its Phase 3 Multikine Trial in Spain

CEL-SCI Corporation announced that Spain’s Agency for Medicinal Products and Medicinal Devices has authorized the company to commence patient enrollment for its ongoing Phase 3 trial of its investigational immunotherapy Multikine (Leukocyte Interleukin, Injection) in patients with advanced primary squamous cell carcinoma of the oral cavity/soft palate, a type of head and neck cancer. Spain is the 22nd country to authorize CEL-SCI’s Phase 3 trial for patient enrollment. Multikine Phase 3 Study: the Multikine Phase 3 study is enrolling patients with advanced primary squamous cell carcinoma of the head and neck. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus standard of care (“SOC”) vs. subjects who are treated with SOC only. Multikine (Leukocyte Interleukin, Injection) is an investigational immunotherapeutic agent that is being tested in an open-label, randomized, controlled, global pivotal Phase 3 clinical trial as a potential first-line treatment for advanced primary squamous cell carcinoma of the head and neck. Multikine is designed to be a different type of therapy in the fight against cancer: one that appears to have the potential to work with the body’s natural immune system in the fight against tumors.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CVM:US $0.65 USD +0.0537

CVM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CVM.
View Industry Companies
 

Industry Analysis

CVM

Industry Average

Valuation CVM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 107.6x
Price/Book 158.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 149.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CEL-SCI CORP, please visit www.cel-sci.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.